Velesco Expands Operations with New Offices in Massachusetts
The new business development office is located in Massachusetts.
Velesco Pharma, a CDMO, has increased its drug formulation, analytical development, and cGMP clinical-trial manufacturing services with the opening of a new business development office in the greater Boston area.
Velesco will be the first life sciences tenant of the Quincy Center for Innovation (QCI), a 12,500 ft2 facility that provides office space and support services to assist start-up companies. The QCI, located in Quincy Massachusetts, is expected to open fully Sept. 1, 2013.
Source: Velesco Pharma
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
